8-K: Allogene Therapeutics Adjusts ALPHA3 Trial Regimen Following Fatal Adverse Event

Allogene Therapeutics, Inc. announced the discontinuation of the ALLO-647 arm in its ALPHA3 study for large B-cell lymphoma due to a Grade 5 adverse event, shifting to a standard lymphodepletion regimen.

Summary

• Allogene Therapeutics, Inc. has selected standard fludarabine and cyclophosphamide (FC) as the lymphodepletion regimen for its ALPHA3 study evaluating cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma (LBCL).
• The arm testing FC plus ALLO-647 (FCA) is now closed to further enrollment.
• This decision was made ahead of the scheduled futility analysis due to a Grade 5 adverse event (hepatic failure from disseminated adenovirus infection) in the FC plus ALLO-647 arm, attributed to ALLO-647.
• The adverse event was deemed unrelated to cema-cel.
• Severe viral infections, when present in the Company's trials, have been attributed in part to immunosuppression from ALLO-647.
• No cases of adenoviral infection or hepatic failure have occurred in participants treated with FC lymphodepletion across the Company's trials.
• None of the Company's trials open to enrollment or pipeline programs now include ALLO-647.
• The Company plans to advance its next-generation AlloCAR T product candidates using the proprietary Dagger Platform Technology, designed to minimize or potentially eliminate the need for standard lymphodepletion.
• The amended ALPHA3 trial will proceed as a randomized study comparing cema-cel after standard FC lymphodepletion to observation (current standard of care).
• Over 50 clinical sites are activated across the United States and Canada.

Sentiment

Score: 4

Explanation: The discontinuation of a trial arm due to a fatal adverse event linked to a key component (ALLO-647) is a significant negative. While the primary drug (cema-cel) was deemed unrelated and the trial continues, the event highlights safety challenges and necessitates a strategic pivot away from ALLO-647, which could impact timelines or development costs for other programs that relied on it. The pivot to Dagger Platform is a positive long-term strategy but introduces new development risks.

Positives

• The Grade 5 adverse event was deemed unrelated to cema-cel, the primary therapeutic candidate.
• The ALPHA3 trial will continue with a revised, standard lymphodepletion regimen, maintaining its statistical design and prespecified study conduct.
• The Company is advancing a next-generation platform (Dagger Platform Technology) designed to potentially eliminate the need for standard lymphodepletion, addressing a key challenge in allogeneic cell therapies.
• Over 50 clinical sites are activated across the United States and Canada, indicating broad reach for patient enrollment.

Negatives

• A Grade 5 (fatal) adverse event occurred in the FC plus ALLO-647 arm of the ALPHA3 study, attributed to ALLO-647.
• The arm testing FC plus ALLO-647 (FCA) has been closed to further enrollment, indicating a setback for that specific regimen.
• The need to discontinue ALLO-647 from all current and pipeline trials suggests a significant issue with this component of their previous regimen.

Risks

• Product candidates are based on novel technologies, making it difficult to predict development time and cost, and regulatory approval.
• Limited pre-clinical and Phase 1 data may not be validated in future clinical trials.
• Product candidates may cause undesirable side effects or have other properties that could halt clinical development, prevent regulatory approval, or limit commercial potential.
• The FDA may disagree with clinical or regulatory plans or the import of clinical results, leading to future delays or requiring additional clinical trials.
• Difficulties may be encountered in enrolling patients in clinical trials.
• Inability to demonstrate safety and efficacy of product candidates in clinical trials, which could prevent or delay regulatory approval and commercialization.
• Challenges with manufacturing or optimizing manufacturing of product candidates.

Future Outlook

The Company intends to continue the ALPHA3 trial with a standard lymphodepletion regimen, expecting the futility analysis comparing MRD conversion in the first half of 2026. They also plan to advance next-generation AlloCAR T product candidates using their proprietary Dagger Platform Technology, which aims to reduce or eliminate the need for standard lymphodepletion.

Management Comments

• The decision to select standard fludarabine and cyclophosphamide (FC) as the lymphodepletion regimen was made in conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee and following consultation with the U.S. Food and Drug Administration (FDA).
• The Grade 5 adverse event was deemed unrelated to cema-cel.
• Severe viral infections, when present across the Company's clinical trials, have been attributed to immunosuppression due in part to ALLO-647.
• The Company will advance its next-generation AlloCAR T product candidates using the proprietary Dagger Platform Technology, which is designed to minimize or potentially eliminate the need for standard lymphodepletion.

Industry Context

This announcement highlights the ongoing challenges and advancements in the allogeneic CAR T-cell therapy space. Lymphodepletion is a critical component of CAR T therapy, and managing its side effects, particularly immunosuppression and associated infections, is a key area of research. Allogene's move away from ALLO-647 and towards a "Dagger Platform Technology" that minimizes lymphodepletion reflects an industry trend towards improving the safety profile and accessibility of off-the-shelf cell therapies. The focus on first-line consolidation for LBCL also positions cema-cel in a competitive and high-need oncology indication.

Comparison to Industry Standards

• The use of standard fludarabine and cyclophosphamide (FC) for lymphodepletion is a common and well-established regimen in CAR T-cell therapy, including for autologous CAR T products like Yescarta (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel) for LBCL, which typically use FC or cyclophosphamide/fludarabine.
• The Grade 5 adverse event attributed to ALLO-647 highlights the unique challenges of allogeneic therapies, particularly with additional immunosuppressive agents. While severe infections are a known risk with CAR T therapies due to lymphodepletion, a fatal event specifically linked to an investigational lymphodepleting agent (ALLO-647) is a significant safety signal that led to its discontinuation.
• The development of the Dagger Platform Technology to minimize or eliminate lymphodepletion represents a potential innovation that could differentiate Allogene from competitors by improving the safety and convenience profile of allogeneic CAR T therapies, addressing a major hurdle for broader adoption compared to current autologous products.

Stakeholder Impact

• Shareholders: Potential negative impact due to the adverse event and discontinuation of a trial arm, which could raise concerns about the company's development pipeline and increase perceived risk. However, the continuation of the main trial and the pivot to a new technology might mitigate long-term concerns.
• Patients: The adverse event highlights safety risks associated with certain components of the treatment regimen. The shift to a standard lymphodepletion regimen aims to improve safety for future participants in the ALPHA3 trial. The Dagger Platform Technology could offer a safer treatment option in the future.
• Employees: May face strategic shifts in research and development focus, particularly those involved with ALLO-647.
• Regulatory Authorities (FDA): Close consultation with the FDA and DSMB indicates ongoing regulatory oversight and adherence to safety protocols. The event will likely lead to increased scrutiny of future filings and trial designs.

Next Steps

• The ALPHA3 trial will proceed as a randomized study comparing cema-cel after standard FC lymphodepletion to observation.
• Futility analysis comparing minimal residual disease (MRD) conversion is expected in the first half of 2026.
• Advance next-generation AlloCAR T product candidates using the proprietary Dagger Platform Technology.

Key Dates

Recommendation

The fatal adverse event and the subsequent discontinuation of the ALLO-647 arm represent a significant setback and negative safety signal for Allogene Therapeutics. While the primary drug, cema-cel, was not implicated, the event underscores the inherent risks in novel cell therapies and the challenges of lymphodepletion. The company's pivot to the Dagger Platform Technology is a strategic move to address these challenges long-term, but it introduces new development uncertainties. Given the mixed signals – a serious safety event balanced by the continuation of the main trial and a promising new technology direction – a "hold" recommendation is appropriate. Investors should monitor the upcoming futility analysis in H1 2026 and further developments regarding the Dagger Platform for clearer indications of future prospects.

Keywords

Allogene Therapeutics, ALLO, ALPHA3 study, cemacabtagene ansegedleucel, cema-cel, large B-cell lymphoma, LBCL, lymphodepletion, fludarabine, cyclophosphamide, ALLO-647, adverse event, hepatic failure, adenovirus infection, AlloCAR T, Dagger Platform Technology, clinical trial, oncology, cell therapy, immunotherapy, FDA, MRD conversion